

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Senanayake *et al.*

Serial No.: Not yet assigned Art Unit: 1621  
Filed: Concurrently herewith Examiner: B. Davis  
For: METHODS OF PREPARING Attorney Docket No.: 4821-522-999  
DIDESMETHYLSIBUTRAMINE  
AND OTHER SIBUTRAMINE  
DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
  - 1a.  A list of all patents, publications, applications, or other information submitted for consideration by the office.
  - 1b. A legible copy of:
    - Each U.S. patent application publication and U.S. and foreign patent;
    - Each publication or that portion which caused it to be listed on the PTO-1449;
    - For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
    - all other information or portion which caused it to be listed on the PTO-1449.
  - 1c.  An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
  - 1d.  Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.
2.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
  - Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
  - Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;

- Before the mailing of the first Office action on the merits;
- Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

*(Check either Item 3a or 3b)*

- 3a.  The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b.  The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- enclosed
- to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

*(Item 3b to be checked if any reference known for more than 3 months)*

4.  This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
- The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:
- enclosed
- to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.

The Certification Statement in Item 5 below is applicable.

5.  Certification Statement (applicable if Item 3a or Item 4 is checked)

*(Check either Item 5a or 5b)*

- 5a.  In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b.  In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

6.  This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

*(Check appropriate Items 6a, 6b and/or 6c)*

- 6a.  A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.

- 6b.  Copies of publications listed on Form PTO-1449 from prior application Serial No. 10/120,503, filed on April 12, 2002, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c.  Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.
7.  This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a.  This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8.  In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:  
*(Check Item 8a, 8b, or 8c)*
- 8a.  satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b.  set forth in the application.
- 8c.  enclosed as an attachment hereto.
9.  The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150.
10.  No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: August 20, 2003

  
Dean L. Fanelli 48,907  
(Reg. No.)

For: Anthony M. Insogna (Reg. No. 35,203)  
**PENNIE & EDMONDS LLP**  
1667 K St., N.W.  
Washington, DC 20006  
(202) 496-4400

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		ATTY DOCKET NO 4821-414-999	APPLICATION NO 10/120,503
		APPLICANT C. Senanayake et al.	
		FILING DATE April 12, 2002	GROUP 1621

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,127,363	10/2000	Doherty et al.			
	AB	6,174,925	01/2001	Bailey et al.			
	AC	6,046,242	11/1998	Emmelmann			
	AD	5,795,880	08/1998	Svec et al.			
	AE	5,780,051	07/1998	Eswara et al.			
	AF	5,733,566	03/1998	Lewis			
	AG	5,719,283	02/1998	Bell et al.			
	AH	5,674,553	10/1997	Shinoda et al.			
	AI	5,639,476	06/1997	Oshlack et al.			
	AJ	5,591,767	01/1997	Mohr et al.			
	AK	5,552,429	09/1996	Wong et al.			
	AL	5,459,164	10/1995	Vargas			
	AM	5,436,272	07/1995	Scheinbaum			
	AN	5,354,556	10/1994	Sparks et al.			
	AO	5,250,534	10/1993	Bell et al.			
	AP	5,120,548	06/1992	McClelland et al.			
	AQ	5,104,899	04/1992	Young et al.			
	AR	5,073,543	12/1991	Marshall et al.			
	AS	5,068,440	11/1991	Jeffery et al.			
	AT	5,059,595	10/1991	Le Grazie			
	AU	4,988,814	01/1991	Abou-Gharbia et al.			
	AV	4,939,175	07/1990	Ukai et al.			
	AW	4,929,629	05/1990	Jeffery			
	AX	4,871,774	10/1989	Rees			
	AY	4,816,488	03/1989	Rees			
	AZ	4,814,352	03/1989	Jeffery et al.			
	BA	4,806,570	02/1989	Jeffery et al.			
	BB	4,746,680	05/1988	Jeffery et al.			
	BC	4,552,828	11/1985	Toya et al.			
	BD	4,522,828	06/1985	Jeffery et al.			
	BE	4,008,719	02/1977	Theeuwes et al.			
	BF	3,960,891	06/1976	Malen et al.			

	BG	3,916,899	11/1975	Theeuwes et al.			
	BH	3,845,770	11/1974	Theeuwes et al.			
	BI	3,598,123	08/1971	Zaffaroni			
	BJ	3,536,809	10/1970	Applezweig			
	BK	3,471,515	10/1969	Troxler et al.			
	BL	3,155,670	11/1964	Janssen et al.			
	BM	3,155,669	11/1964	Janssen et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BN	WO 00/56322	09/2000	PCT				
	BO	WO 00/56321	09/2000	PCT				
	BP	WO 00/56318	09/2000	PCT				
	BQ	WO 00/56315	09/2000	PCT				
	BR	WO 00/56314	09/2000	PCT				
	BS	WO 00/56309	09/2000	PCT				
	BT	WO 00/56306	09/2000	PCT				
	BU	WO 00/56151	09/2000	PCT				
	BV	WO 00/56150	09/2000	PCT				
	BW	WO 00/56149	09/2000	PCT				
	BX	WO 00/56148	09/2000	PCT				
	BY	WO 00/54765	09/2000	PCT				
	BZ	WO 00/32182	11/1998	PCT				
	CA	WO 99/33450	07/1999	PCT				
	CB	WO 98/13034	04/1998	PCT				
	CC	WO 98/13033	04/1998	PCT				
	CD	WO 98/11884	03/1998	PCT				
	CE	WO 98/06722	02/1998	PCT				
	CF	EP 0 781 561 A1	07/1997	EPO				
	CG	WO 97/20810	06/1997	PCT				
	CH	WO 97/03675	02/1997	PCT				
	CI	WO 95/21615	08/1995	PCT				
	CJ	WO 95/20949	08/1995	PCT				
	CK	WO 94/28902	12/1994	PCT				
	CL	WO 94/00114	01/1994	PCT				
	CM	WO 94/00047	01/1994	PCT				
	CN	WO 90/06110	06/1990	PCT				
	CO	WO 88/06444	09/1988	PCT				
	CP	DE 32 12 682 A1	10/1982	Germany				
	CQ	GB 2098602 A	11/1982	United Kingdom				

CR	EP 0 035 597	9/1981	Europe			
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
CS	Baldessarini et al., <i>Life Sciences</i> 39: 1765-1777, (1986).					
CT	Buckett et al., "BTS 54 524-An Approach to Rapidly Acting Antidepressant," <i>New Concepts in Depression</i> 2: 167-172 (1988).					
CU	Bucket et al., "The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation", <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> 12: 575-584 (1988).					
CV	Buckett et al., "Sibutramine Hydrochloride," <i>Drugs of the Future</i> 13(8): 736-738 (1988).					
CW	Butler, D., <i>Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide</i> , J. Org. Chem., 36:1308-1309 (1971)					
CX	Canonne, P., et al., <i>Effet du Benzene Dans la Reaction de Grignard sur les Nitriles</i> , <i>Tetrahedron Lett.</i> , 21:155-58 (1980)					
CY	Carstensen, J., <i>Drug Stability: Principles &amp; Practice</i> , 2d. Ed., pp. 379-80, Marcel Dekker, NY, NY, (1995).					
CZ	Castello, R.A., et al., <i>Discoloration of Tablets Containing Amines and Lactose</i> , <i>Pharm. Sci.</i> 51(2):106-108 (1962)					
DA	Cheetham, S.C., et al., <i><sup>3</sup>H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with <sup>3</sup>H5-HT Uptake: Effect of Administration of Various Antidepressant Treatments</i> , <i>Neuropharmacology</i> (1993), 32(8), 737-743					
DB	Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT <sub>1A</sub> Receptors, <i>Med. Chem.</i> , 36:1509-1510 (1993)					
DC	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fourth Ed., American Psychiatric Association, (1997).					
DD	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 3rd Ed., American Psychiatric Association (1981).					
DE	Dreshfield et al., <i>Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin (5-HT) Levels by (-)-Pindolol, an Antagonist at 5-HT<sub>1A</sub> Receptors</i> , <i>Neurochem. Res.</i> , 21(5):557-562 (1996)					
DF	Eliel, E.L., <i>Stereochemistry of Carbon Compounds</i> (McGraw-Hill, NY, 1962).					
DG	Evans et al., "Prevalence of Alzheimer's Disease in a Community Population of Older Persons," <i>J.A.M.A.</i> 262: 2551-2556 (1989).					
DH	Fuentes, J. et al., "Comparison of the apparent anti-depressant activity of (-) and (+) tranylpromine in an animal model", <i>Chemical Abstracts</i> , 85: 7, page 31, No. 40768t (1976).					
DI	Goodman & Gilman, <i>The Pharmacological Basis of Therapeutics</i> , 362-373, 404 (9 <sup>th</sup> ed. McGraw-Hill, 1996)					
DJ	Gray et al., <i>The Involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds</i> , <i>BR.J. Pharmacol.</i> , Vol. 124, No. 4, (1998) pp 669-674					
DK	<i>Handbook of Pharmaceutical Excipients</i> , 2 <sup>nd</sup> ed., Wade and Willer eds., pp. 257-259 (1994)					
DL	Heal et al., <i>A Comparison of the Effects on Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents</i> , <i>BR.J. Pharmacol.</i> (1998), 125(2), 301-308					
DM	Hillver et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralix: A Putative 5-HT <sub>1A</sub> Receptor Antagonist, <i>J. Med. Chem.</i> , 33:1541-44 (1990)					
DN	<i>J. Med. Chem.</i> , Vol. 36, No. 17, 2540 (1993)					
DO	<i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed., Lea & Febiger, Philadelphia (1985).					
DP	Jacques et al., "Enantiomers, Racemates and Resolutions," (Wiley-Interscience, NY, 1981).					
DQ	Jamali et al., <i>Journal of Pharmaceutical Sciences</i> , 78: 9: 695-715 (1989)					
DR	Jeffery et al., <i>Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites</i> , <i>J. Chem. Soc. Perkin. Trans. 1</i> , 2583-2589 (1996)					

	DS	King et al., "Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers," <i>Clinical Pharmac.</i> 26: 607-611 (1989).
	DT	Kula et al., "Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synatosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species," <i>Life Sciences</i> 34(26): 2567-2575, (1984).
	DU	Luscombe et al., <i>The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride</i> , Neuropharmacology, Vol. 28, No. 2, (1989) pp 129-134
	DV	The Merck Manual of Diagnosis and Therapy, ??th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
	DW	Middlemiss et al., <i>Centrally Active 5-HT Receptor Agonists and Antagonists</i> , Neurosci. and Biobehv. Rev., 16:75-82 (1992)
	DX	Moreau et al., <i>Behavioral Profile of the 5-HT<sub>1A</sub> Receptor Antagonist (S)-UH-301 in Rodents and Monkeys</i> , <i>Brain Res. Bull.</i> , 29:901-04 (1992)
	DY	Nakada et al., <i>An Enantioconvergent Route to (-)-Kainic Acid</i> , <i>Tetrahedron Lett.</i> , 38:857-860 (1997)
	DZ	<i>Physician's Desk Reference®</i> 473-475 (53 <sup>rd</sup> ed., 1999)
	EA	<i>Physician's Desk Reference®</i> 475-476 (53 <sup>rd</sup> ed., 1999)
	EB	<i>Physician's Desk Reference®</i> 764-766 (53 <sup>rd</sup> ed., 1999)
	EC	<i>Physician's Desk Reference®</i> 823-825 (53 <sup>rd</sup> ed., 1999)
	ED	<i>Physician's Desk Reference®</i> 978-979 (53 <sup>rd</sup> ed., 1999)
	EE	<i>Physician's Desk Reference®</i> 1054-1056 (53 <sup>rd</sup> ed., 1999)
	EF	<i>Physician's Desk Reference®</i> 1332-1334 (53 <sup>rd</sup> ed., 1999)
	EG	<i>Physician's Desk Reference®</i> 1369-1370 (53 <sup>rd</sup> ed., 1999)
	EH	<i>Physician's Desk Reference®</i> 1432-1436 (53 <sup>rd</sup> ed., 1999)
	EI	<i>Physician's Desk Reference®</i> 1494-1498 (53 <sup>rd</sup> ed., 1999)
	EJ	<i>Physician's Desk Reference®</i> 1641-1645 (53 <sup>rd</sup> ed., 1999)
	EK	<i>Physician's Desk Reference®</i> 2004-2009 (53 <sup>rd</sup> ed., 1999)
	EL	<i>Physician's Desk Reference®</i> 2075-2078 (53 <sup>rd</sup> ed., 1999)
	EM	<i>Physician's Desk Reference®</i> 2190-2192 (53 <sup>rd</sup> ed., 1999)
	EN	<i>Physician's Desk Reference®</i> 2367-2368 (53 <sup>rd</sup> ed., 1999)
	EO	<i>Physician's Desk Reference®</i> 2396-2399 (53 <sup>rd</sup> ed., 1999)
	EP	<i>Physician's Desk Reference®</i> 2490-2493 (53 <sup>rd</sup> ed., 1999)
	EQ	<i>Physician's Desk Reference®</i> 2516-2521 (53 <sup>rd</sup> ed., 1999)
	ER	<i>Physician's Desk Reference®</i> 2688-2691 (53 <sup>rd</sup> ed., 1999)
	ES	<i>Physician's Desk Reference®</i> 2701-2704 (53 <sup>rd</sup> ed., 1999)
	ET	<i>Physician's Desk Reference®</i> 2720-2726 (53 <sup>rd</sup> ed., 1999)
	EU	<i>Physician's Desk Reference®</i> 2735-2736 (53 <sup>rd</sup> ed., 1999)
	EV	<i>Physician's Desk Reference®</i> 2886-2888 (53 <sup>rd</sup> ed., 1999)
	EW	<i>Physician's Desk Reference®</i> 2908-2910 (53 <sup>rd</sup> ed., 1999)
	EX	<i>Physician's Desk Reference®</i> 3092-3094 (53 <sup>rd</sup> ed., 1999)
	EY	<i>Physician's Desk Reference®</i> 3101-3104 (53 <sup>rd</sup> ed., 1999)

	EZ	<i>Physician's Desk Reference®</i> 3224-3225 (53 <sup>rd</sup> ed., 1999)
	FA	<i>Physician's Desk Reference®</i> 3267-3272 (53 <sup>rd</sup> ed., 1999)
	FB	<i>Physician's Desk Reference®</i> 3307-3309 (53 <sup>rd</sup> ed., 1999)
	FC	<i>Physician's Desk Reference®</i> 3383-3384 (53 <sup>rd</sup> ed., 1999)
	FD	<i>Physician's Desk Reference®</i> 2520 (52 <sup>nd</sup> ed., 1998)
	FE	<i>Physician's Desk Reference®</i> 2958 (52 <sup>nd</sup> ed., 1998)
	FF	Remingtons: <i>The Practice of The Science and Pharmacy</i> , 19 <sup>th</sup> ed., Gennaro, ed., p. 1625 (1995)
	FG	<i>Remington's Pharmaceutical Sciences</i> , 18th ed., Mack Publishing, Easton PA (1990).
	FH	<i>Remington's Pharmaceutical Sciences</i> , 16th ed., Mack Publishing, Easton PA (1980).
	FI	Stock, M.J., <i>Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent</i> , Int'l J. Obesity, 21(Supp. 1):S25-S29 (1997)
	FJ	U.S. <i>Pharmacopia (USP) SP (XXI)/NF (XVI)</i>
	FK	Wilen et al., <i>Tetrahedron</i> , 2725-36 33(21) (1977).
	FL	Wilen, S.H., <i>Tables of Resolving Agents and Optical Resolutions</i> 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		